Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2024. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs). It does not contain financial performance results for the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Transaction 1: Purchase of 3,500 Ordinary Shares at £15.7062 per share.
- Transaction 2: Purchase of 19,360 Ordinary Shares at £15.8280 per share.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses two separate purchases of GSK plc ordinary shares on the London Stock Exchange (XLON) on February 1, 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific equity transactions.
Important Facts for Investors
- Insider Buying: Two insiders purchased shares on the same day (Feb 1, 2024), totaling 22,860 shares.
- Participants:
- Lady Susan Symonds (PCA of Non-Executive Chair Sir Jonathan Symonds) purchased 3,500 shares.
- Julie Brown (Chief Financial Officer) purchased 19,360 shares.
- Transaction Venue: All trades occurred on the London Stock Exchange.
- No Financial Results: This filing does not report quarterly or annual earnings.